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ABSTRACT 
Protein phosphatase type 1 (PP1) plays a major role in the regulation of 
glycogen biosynthesis. PP1 is recruited to sites of glycogen formation by its 
binding to specific targeting subunits. There, it dephosphorylates different 
enzymes involved in glycogen homeostasis leading to an activation of glycogen 
biosynthesis. Regulation of these targeting subunits is crucial, as excess of 
them leads to an enhancement of the action of PP1, which results in glycogen 
accumulation. In this work we present evidence that PPP1R3D (R6), one of the 
PP1 glycogenic targeting subunits, interacts physically with laforin, a glucan 
phosphatase involved in Lafora disease, a fatal type of progressive myoclonus 
epilepsy. Binding of R6 to laforin allows the ubiquitination of R6 by the E3-
ubiquitin ligase malin, what targets R6 for autophagic degradation. As a result of 
the action of the laforin-malin complex on R6, its glycogenic activity is 
downregulated. Since R6 is expressed in brain, our results suggest that the 
laforin-malin complex downregulates the glycogenic activity of R6 present in 
neuron cells to prevent glycogen accumulation. 
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1. INTRODUCTION 
Protein phosphatase 1 (PP1) is a serine/threonine protein phosphatase which 
plays important roles in the regulation of a broad range of physiological 
processes, including cell proliferation, differentiation, survival and death (Heroes 
et al. , 2012). In the later years it has become evident that free PP1 has 
essentially no specificity for substrates, its specificity being regulated by more 
than 200 PP1-interacting proteins (PIPs), which create a vast variety of PP1 
holoenzymes with a distinct subset of substrates and mechanisms of regulation 
(Bollen et al. , 2010, Heroes, Lesage, 2012). One of the processes regulated by 
PP1 is glycogen homeostasis. In this case, PP1 interacts with a specific set of 
glycogen targeting subunits which contain a carbohydrate binding module of the 
CBM21 type. Seven recognized glycogen targeting subunits have been 
identified, namely PPP1R3A (GM), PPP1R3B (GL), PPP1R3C (R5/PTG), 
PPP1R3D (R6), PPP1R3E (R3E), PPP1R3F (R3F) and PPP1R3G (R3G) (in 
brackets, the informal name) (Heroes, Lesage, 2012). These subunits target 
PP1 to specific enzymes involved in glycogen homeostasis: they bind glycogen 
synthase (GS), allowing in this way the dephosphorylation of the synthase and 
its activation; they also bind glycogen phosphorylase (Ph) and glycogen 
phosphorylase kinase (PhK), allowing the dephosphorylation and inactivation of 
these enzymes. In this way the net action of PP1 on glycogen homeostasis is to 
improve glycogen accumulation, since it promotes the synthesis of the 
polysaccharide and prevents its degradation (Roach et al. , 2012). Although 
these subunits bind to PP1 through a similar RVxF docking motif, they are 
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structurally different and more importantly, their function is regulated by different 
mechanisms depending on the corresponding subunit. For example, the activity 
of GM is regulated by phosphorylation of the subunit by PKA, whereas the 
activity of GL is inhibited allosterically by the binding of Ph to the C-terminus of 
the regulatory subunit (Roach, Depaoli-Roach, 2012). 
 The PP1-PPP1R3X holoenzymes play a main role in glucose homeostasis 
since they regulate glycogen synthesis and degradation in key tissues such as 
liver and skeletal muscle. In addition, the participation of R5/PTG in the 
regulation of glycogen synthesis in the neurons has been described recently. In 
fact, enhancement of R5/PTG function leads to the accumulation of insoluble 
polyglucosans in neuronal cells (Vilchez et al. , 2007), and R5/PTG is 
associated with a fatal type of progressive myoclonus epilepsy named Lafora 
disease (LD, OMIM 254780). This disease is produced by mutations in either 
the EPM2A gene, encoding the glucan phosphatase laforin, or the EPM2B 
gene, encoding the E3-ubiquitin ligase malin. These two proteins form a 
functional complex and defects in any of them lead to the disease, which 
correlates with the appearance of poorly-branched insoluble polyglucosans 
named Lafora bodies. It has been proposed that the laforin-malin complex 
interacts with R5/PTG and ubiquitinates it, impairing its glycogenic activity 
[(Vilchez, Ros, 2007), (Solaz-Fuster et al. , 2008), (Worby et al. , 2008)]. In 
addition, we have recently reported that the key metabolic sensor AMP-
activated protein kinase (AMPK), on one hand enhances the function of the 
laforin-malin complex, and on the other hand, it is able to phosphorylate 
R5/PTG, facilitating in this way the recognition of this subunit by the laforin-
malin complex and its ubiquitination [(Solaz-Fuster, Gimeno-Alcaniz, 2008), 
(Vernia et al. , 2009)]. 
 Very little is known about the mechanism of regulation of R6 (PPP1R3D) 
activity. Since R6 is expressed in brain [(Armstrong et al. , 1997), (Esteves et al. 
, 2012)], this subunit could also have a role in regulating glycogen synthesis in 
this organ. For this reason we analyze the glycogenic activity of this subunit and 
whether the activity of R6 could also be regulated by the laforin-malin complex. 
In this work we present evidence of a physical interaction between laforin and 
R6. This interaction leads to the malin-dependent ubiquitination of R6, which is 
targeted for autophagic degradation. Using a neuronal cell model (Neuro-2a), 
we also show that R6, laforin, malin and glycogen synthase are located in 
similar cytosolic areas of the cell, revealing a common role of these proteins on 
the regulation of glycogen homeostasis in this neuronal cell type. 
 
 
2. MATERIALS AND METHODS 
2.1. Plasmids. pCMV-HA-laforin, pcDNA3-HA-malin and pFlag-R6 constructs 
were described previously [(Solaz-Fuster, Gimeno-Alcaniz, 2008), (Garcia-Haro 
et al. , 2010)]. pBTM-R6 and pGADT7-R6 plasmids were obtained by digesting 
a R6 plasmid (Worby, Gentry, 2008) with EcoRI/XhoI and subcloning the 
fragment containing the R6 open reading frame (ORF) into pBTM116 
(EcoRI/SalI) or pGADT7 plasmids, respectively. Plasmid pEYFP-R6 was 
obtained by digesting plasmid pGADT7-R6 with HindIII/KpnI and subcloning the 
resulting fragment into pEYFP-C1 (BD Biosciences, Madrid, Spain). Plasmid 
pCMV-myc-R6 was obtained by digesting pGADT7-R6 with SfiI/XhoI and 
subcloning the resulting fragment into pCMVmyc (BD Biosciences, Madrid, 
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Spain). Other plasmids used in this study were pCMV-6xHisUbiq (from Dr. M. 
Rodriguez, Proteomics Unit, CIC-BioGUNE, Vizcaya, Spain); pCMV-6xHisUbiq 
K48R and pCMV-6xHisUbiq K63R (from Dr. Ch. Blattner, Institute of Toxicology 
and Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany); pCMV-
Mdm2 [from Dr. M. Gentry, University of Kentucky, Lexington, KY; (Worby, 
Gentry, 2008)]; pCMV-6xHisHAUbiq KO was kindly provided by Dr. W. Gu 
[Institute of Cancer Genetics, Columbia University, New York, USA; (Li et al. , 
2003)] and pCFP-laforin was a generous gift from Dr. Romá-Mateo (IBV-CSIC, 
Valencia, Spain). 
 
2.2. Cell Culture, Transfection and Treatments. Murine neuroblastoma 
Neuro-2a (N2a) and human embryonic kidney (HEK-293) cells were grown in 
Dulbecco’s modified Eagle’s medium (Lonza, Barcelona, Spain), supplemented 
with 100 units/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine and 10% 
of inactivated fetal bovine serum (Invitrogen, Madrid, Spain) in a humidified 
atmosphere at 37ºC with 5% CO2. Cells were transfected with 1 μg of each 
plasmid using X-treme GENE HP transfection reagent (Roche Diagnostics, 
Barcelona, Spain) according to the manufacturer’s instructions. When indicated, 
eighteen hours after transfection, cells were treated with MG132 (25 μM), 
ammonium chloride (20 mM)/ leupeptin (100 μM) or lactacystin (5 μM) for 6 
hours. Cell extracts were prepared using lysis buffer [25 mM Tris HCl at pH 7.4, 
15 mM EDTA at pH 8, 50 mM NaF, 0.6 M sucrose, 15 mM 2-mercaptoethanol, 
15 mM Na2P2O7, 1 mM PMSF, and a complete Mini-EDTA free protease 
inhibitor mixture (Roche Diagnostics, Barcelona, Spain)]. Cells were lysed by 
repeated passage through 24Gx5/8’’ needle. Twenty micrograms of total protein 
from the soluble fraction of cell lysates were analyzed by SDS-PAGE and 
Western blotting using appropriated antibodies: anti-myc, anti-Flag, anti-HA 
(Sigma-Aldrich, Madrid, Spain); anti-tubulin, anti-Mdm2, anti-LexA (Santa Cruz 
Biotechnology, Barcelona, Spain),  
 
2.3. Yeast two-hybrid analysis. Yeast THY-AP4 strain [MATα ura3 leu2 trp1 
lexA::lacZ lexA::HIS3 lexA::ADE2] (Paumi et al. , 2007) was transformed with 
plasmids pBTM-R6 (LexA-R6) and pACT2 (GAD, empty plasmid), pACT2-malin 
(GAD-malin) or pACT2-laforin (GAD-laforin), or with pGADT7-R6 (GAD-R6) and 
plasmids pBTM (LexA, empty plasmid), pBTM-malin (LexA-malin) or pEG202-
laforin (LexA-laforin). Transformants were grown in selective SC medium, and 
β-galactosidase activity was assayed in permeabilized cells and expressed in 
Miller units as in (Ludin et al. , 1998). 
 
2.4 Co-immunoprecipitation analysis. Neuro-2a cells were transfected with 
pCMV-HA-laforin and pCMV-myc-R6 or with the corresponding empty plasmids. 
Cells were scraped on ice in lysis buffer [50 mM Tris–HCl pH 8; 10 mM KCl, 50 
mM EDTA; 15% glycerol, 1% nonidet P-40 (NP-40), complete protease inhibitor 
cocktail (Roche Diagnostics, Barcelona, Spain), 1 mM PMSF, 50 mM NaF, 2 
mM NaVO4 and 5 mM Na2P2O7]. Cell lysis was performed as described above. 
Cell lysates were then centrifuged at 13,000x g for 15 min at 4ºC. R6-laforin 
complexes were immunoprecipitated from supernatants (500 μg of total protein) 
with anti-myc polyclonal antibody (Sigma-Aldrich, Madrid, Spain) and visualized 
by immunoblotting using anti-myc-HRP or anti-HA-HRP (Sigma-Aldrich, Madrid, 
Spain) antibodies. 
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2.5. Study of in vivo ubiquitination of R6. For ubiquitination assays, HEK-293 
cells were co-transfected with pCMV-myc-R6, 6xHis-tagged ubiquitin plasmids 
and, when indicated, with pcDNA3-HA-malin and pCMV-HA-laforin plasmids, 
using X-treme GENE transfection reagent, according to the manufacturer’s 
instructions (Roche Diagnostics, Barcelona, Spain). After 18 h of transfection, 
when indicated, cell were treated with MG132 (25 μM) for 6 hours. Then cells 
were lysed and ubiquitinated proteins purified by metal affinity chromatography 
(Kaiser and Tagwerker, 2005). Bound proteins and clarified extracts were 
analyzed by immunoblotting with the appropriated antibodies. 
 
2.6. Glycogen determination.  Neuro-2a transfected cells were scraped on ice 
into 30% KOH and then heated at 100ºC for 15 min. Glycogen was measured 
as described previously (Chan and Exton, 1976) and expressed as μg of 
glucose per mg of protein. 
 
2.7. Immunofluorescence and confocal microscopy. Neuro-2a cells 
transfected with the indicated plasmids were grown on 12-well plates containing 
coverslips. Cells were fixed with 4% paraformaldehyde in phosphate-buffered 
saline (PBS) for 10 min. For direct fluorescence, cells were washed three times 
with PBS and stained with 4',6-diamidino-2-phenylindole (DAPI) for 10 min, in 
order to visualize the nuclei. Then, cells were washed three times with PBS and 
mounted on slices using Aqua-Poly/Mount coverslipping medium (Polysciences, 
Inc. Eppelheim, Germany). For immunofluorescence, cells were permeabilized 
with 0.2% Triton X-100 in PBS for 15 min. Then, cells were washed three times 
with PBS and blocked one hour with 10% fetal bovine serum, 5% nonfat dried 
milk, and 0.1% Triton X-100 in PBS, for anti-HA antibody, or with 3% BSA in 
PBS for glycogen synthase antibody. Cells were then incubated overnight at 
4ºC with 1/200 dilution of anti-HA (Sigma-Aldrich, Madrid, Spain) or anti-GS 
(rabbit monoclonal antibody against the C-term of muscular glycogen synthase; 
Epitomics/AntibodyBcn, Barcelona, Spain) in blocking solution. Samples were 
washed three times with PBS and incubated with a 1/500 dilution of anti-mouse 
Alexa-Fluor 633 or anti-rabbit Alexa-Fluor 633 (Invitrogen, Madrid, Spain), 
respectively. Finally, samples were processed as described above for direct 
fluorescence. For R6 subcellular localization, images were acquired with a 
upright Leica DM RXA2 microscope and for co-localization assays with a Leica 
TCS SL confocal microscope (Leica, Wetzlar, Germany) using an PL APO 63x 
oil 1.4 N.A. immersion objective. Images were treated with the ImageJ 1.43c 
software (Wayne Ras-band, National Institutes of Health, Bethesda, MD). 
 
2.8 FRET experiments. Fluorescence Resonance Energy Transfer (FRET) 
measurements were performed using the acceptor photobleaching approach 
(Karpova et al. , 2003). Cyan and yellow fluorescence protein (CFP and EYFP) 
were used as the respective donor and acceptor FRET pair. A 458 nm 
excitation laser line and a 465-510 nm band width for emission for CFP and a 
514 nm excitation laser line and a 525-650 nm band width for emission for 
EYFP were used as donor and acceptor channels. Neuro-2a cells were 
transfected with either pEYFP-R6 (acceptor) + pCFP-laforin (donor) or pEYFP 
(empty) + pCFP-laforin plasmids. FRET efficiency was accomplished by 
comparing the donor’s fluorescence intensity in the cells transfected with both 
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donor and acceptor fluorescent proteins before (prebleached) and after 
(postbleached) depleting the acceptor fluorescence at least 60% of the initial 
fluorescence by photobleaching. FRET efficiency values were obtained using 
the following equation: FRETeff(%)= [(Donor postbleached – Donor prebleached) / 
Donor postbleached ) x100]. Images (8 bits, 512 x 512 pixels, two airy pinhole units 
and 2.7 x zoom) were taken in a Leica TCS SL confocal microscope with a PL 
APO 63x 1.4 N.A. oil objective using the Leica Confocal Software (Leica, 
Wetzlar, Germany). If FRET is present, the fluorescence intensity of donor 
should increase after acceptor is photobleached.  
 
2.9 Statistical data analysis. Data are expressed as means with standard 
deviation. Statistical significance of differences between the groups was 
evaluated by a paired Student’s t-test with two-tailed distribution. The 
significance has been considered at * p < 0.05, ** p < 0.01, *** p < 0.001, as 
indicated in each case. 
 
 
3. RESULTS 
3.1. Laforin interacts with the PP1 glycogenic regulatory subunit R6 
In order to study a possible relationship between the PP1 glycogen targeting 
subunit R6 (PPP1R3D) and laforin or/and malin, we performed yeast-two hybrid 
assays. As shown in Figure 1 (left panel), we detected a solid two-hybrid 
interaction between R6 and laforin but not with malin, even though both proteins 
were expressed at the same level (Fig.1, right panel). There was no difference 
in the strength of interaction when using different protein fusions (LexA or 
GAD), confirming the positive interaction between R6 and laforin. Since laforin 
and malin form a functional complex, we carried out also yeast triple-hybrid 
assays overexpressing in addition either malin or laforin, but this strategy did 
not improve the interaction between the corresponding partners (data not 
shown). 
 To validate the interaction between R6 and laforin in mammalian cells we 
performed a co-immunoprecipitation approach. We overexpressed in a murine 
neuroblastoma cell line, Neuro-2a (N2a), a myc-tagged R6 plasmid and laforin 
labeled with HA. Myc-R6 was immunoprecipitated using an anti-myc antibody, 
and HA-laforin appeared in the co-immunoprecipitates but only when R6 was 
present (Fig. 2A), indicating that R6 is able to interact with laforin in mammalian 
cells. 
 We took advantage of fluorescent resonance energy transfer (FRET) 
technology to confirm the interaction between R6 and laforin. We constructed a 
R6 fusion protein with yellow fluorescent protein (EYFP) attached on its N-
terminus as a FRET acceptor. As a donor we used a cyan fluorescent protein 
(CFP) fused to the N-terminus of laforin. When both constructs were co-
expressed in N2a cells, a FRET signal was observed which was significantly 
higher than the one present in cells expressing EYFP alone and CFP-laforin 
(Fig. 2B), indicating that laforin and R6 are close enough to enable energy 
transfer. All these results indicate a physical interaction between laforin and R6. 
 
3.2. The laforin-malin complex is able to ubiquitinate R6 
Malin is a RING-type E3-ubiquitin ligase able to ubiquitinate itself and its partner 
protein laforin, as well as other proteins related to energy metabolism, such as 
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AMPK or other PP1 regulatory subunits like R5/PTG [(Solaz-Fuster, Gimeno-
Alcaniz, 2008), (Moreno et al. , 2010)]. It has been reported that laforin may 
recruit specific substrates to be ubiquitinated by malin. Thus, laforin and malin 
act as a functional complex regulating the ubiquitination of many substrates. As 
we have observed the interaction of R6 with laforin, we decided to analyze if 
laforin could recognize R6 as a putative malin substrate. With this aim, we 
performed an ubiquitination assay in HEK-293 cells using a 6xHis tagged 
ubiquitin. Cells were lysed in denaturing buffer containing the chaotropic agent 
guanidinium hydrochloride to prevent the action of deubiquitinating enzymes 
(Kaiser and Tagwerker, 2005). To detect R6-ubiquitinated forms, we purified the 
ubiquitinated proteins by metal-affinity chromatography. Then, we analyzed the 
affinity-purified ubiquitin conjugates by SDS-PAGE and Western blot analysis 
using specific antibodies against the protein of interest (Fig. 3). We noted a 
discrete pattern of R6 ubiquitination due to the presence of both malin and 
laforin proteins (Fig. 3, lane 4). Although at lower intensity, ubiquitinated forms 
of R6 were also present if only malin was overexpressed, probably due to the 
presence of endogenous laforin in HEK-293 cells (Fig. 3, lane 3). No major 
ubiquitinated forms were detected when only laforin was overexpressed (Fig. 3, 
lane 2) or in the absence of overexpressed laforin and malin (Fig. 3, lane 1). 
These data indicate that a functional laforin-malin complex is needed to carry 
out R6 ubiquitination, supporting our previous results indicating that laforin 
assists in malin-directed ubiquitination.  
 To evaluate the specificity of malin-dependent R6 ubiquitination, we tested 
if another RING-type E3 ubiquitin ligase could ubiquitinate R6. With this 
purpose, we overexpressed R6 in combination with Mdm2, a known p53 
ubiquitin ligase. In this case, no ubiquitinated bands of R6 appeared (Fig. 3C), 
verifying the specificity of this posttranslational modification. Notably, the malin-
dependent ubiquitination pattern of R6 is different from the one from R5/PTG, a 
known substrate of the laforin-malin complex [(Solaz-Fuster, Gimeno-Alcaniz, 
2008), (Worby, Gentry, 2008)]. While R6 ubiquitination pattern presents a major 
predominant band, corresponding probably to the incorporation of two ubiquitin 
moieties, in R5/PTG predominates the presence of ubiquitinated conjugates of 
high molecular weight (Fig.3B, compare lanes 4 and 6). 
 It has been reported that the laforin-malin complex induces the 
polyubiquitination of R5/PTG and AMPK β-subunits via Lys63-linked ubiquitin 
chains (Moreno, Towler, 2010). In order to elucidate the topology of the 
ubiquitin chains present on R6, we overexpressed 6xHis-ubiquitin mutants in 
which residues lysine 48 or 63 were replaced by arginine. To improve the 
accumulation of ubiquitinated proteins we used the proteasomal inhibitor 
MG132. As we can observe in Fig. 4, when the K48R ubiquitin mutant was 
used, R6-ubiquitinated levels were similar to wild type (lanes 5 and 6 in 
comparison to lanes 3 and 4), indicating that the residue K48 of ubiquitin is not 
essential in the process. On the contrary, when the K63 residue was mutated to 
arginine, the formation of high molecular weight ubiquitin conjugates was 
prevented, demonstrating the importance of this residue in the ubiquitin chain 
formation (Fig. 4, lane 7 and 8). However, this mutant did not prevent the 
formation of R6-ubiquitinated species containing only one ubiquitin moiety (Fig. 
4, lanes 7 and 8).  
 To ascertain the topology of ubiquitin linkages incorporated by malin on 
R6, we performed an ubiquitination assay employing a lysine-less ubiquitin 
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(KO), which has all the seven lysine residues mutated by arginine and hence, it 
cannot form ubiquitin chains (Fig. 4, lanes 9 and 10). As expected, this KO-
ubiquitin mutant prevented the formation of high molecular weight polyubiquitin 
chains (Fig. 4, lanes 9 and 10). However, a predominant band remained at the 
molecular weight corresponding to +1 ubiquitin attached to R6. These results 
support the data presented above with the K63R mutant, where only a similar 
major band was detected (Fig. 4, lane 7 and 8). These findings indicate that 
malin promotes the incorporation of a single ubiquitin moiety in one site on R6. 
Thus, R6 is the first substrate of the laforin-malin complex which is mono-
ubiquitinated. When using the KO-ubiquitin form we also detected a band 
corresponding to +2 ubiquitins (Fig. 4, lanes 9 and 10), which was also present 
when wild type ubiquitin was present in the assay (Fig. 4, lanes 3 and 4). 
Curiously, this band is the main form when using Flag-R6 as substrate (Fig. 3, 
lane 4). The difference in the ubiquitination pattern between the experiments 
described in Fig. 3 and 4 could be due to different accessibility of the laforin-
malin complex to the distinct tagged-R6 forms. Taking all these results together, 
we suggest that the laforin-malin complex, in addition to its recognized role 
attaching K63-linked ubiquitin chains on its corresponding substrate, may also 
produce the mono/multi-ubiquitination of the substrate, as in the case of R6. 
 
3.3. R6 glycogenic activity is impaired by the laforin-malin complex in N2a 
cells 
Next, we tested the possible effect of the laforin-malin complex on the 
glycogenic activity of R6. First of all, we measured the increase in glycogen 
levels as a consequence of R6 overexpression in N2a cells. When these cells 
were transfected with an empty vector, the levels of glycogen were almost 
undetectable, suggesting an auto-inactivated state of the glycogenic machinery 
(Vilchez, Ros, 2007). On the contrary, when R6 was overexpressed, glycogen 
levels were detected at high levels. This effect was dose-dependent on the 
amount of R6 present, indicating that the glycogenic activity was dependent on 
the expression of R6 (Fig. 5A). The glycogenic activity of R6 was due to an 
activation of endogenous glycogen synthase activity in these cells, 
demonstrated by the appearance of faster mobility dephosphorylated bands, as 
suggested by western blotting analysis (Fig. 5B, left panel). We could not detect 
an effect of R6 on the phosphorylation status of endogenous phosphorylase, 
probably due to the low amount of this enzyme present in N2a cells. However, 
we detected a robust interaction between R6 and phosphorylase by yeast two-
hybrid analysis (Fig. 5B, right panel), indicating that an effect of R6 on 
endogenous phosphorylase is likely to occur. 
Then, we co-transfected N2a cells with plasmids expressing R6, malin 
and laforin. This led to a down-regulation of both glycogen and R6 protein levels 
(Fig. 5C), reaching a 50% decrease of glycogen production when laforin and 
malin were present. These data were in agreement with a reported 
downregulation of the glycogenic activity of R6 by the laforin-malin complex in 
CHO-IR cells (Worby, Gentry, 2008). Therefore, the laforin-malin complex is 
able to downregulate R6 protein levels, leading to a decrease in its glycogenic 
activity. 
 
3.4. Laforin-malin dependent ubiquitination of R6 leads to its lysosomal 
degradation 
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To analyze whether the laforin-malin dependent ubiquitination of R6 could mark 
it for proteasomal degradation, we decided to inhibit proteasome activity and 
check whether this prevented the downregulation of R6 protein levels by the 
laforin-malin complex. With this purpose, we transfected HEK-293 cells with 
plasmids expressing only R6, or R6, laforin and malin. Then, cells were treated 
with the proteasomal inhibitor lactacystin. In cells expressing only R6, no 
differences were observed on the steady-state protein levels of R6 when using 
lactacystin in comparison to untreated cells (Fig. 6A, compare lane 1 and 3). 
Cells co-expressing R6 and the laforin-malin complex presented lower levels of 
R6 protein (Fig. 6A, lane 4), and these levels did not increase in cells treated 
with lactacystin (Fig. 6A, lane 6). All these results demonstrate that the laforin-
malin induced downregulation of R6 occurs by a proteasome-independent 
manner. 
Subsequently, we tested whether the laforin-malin dependent 
ubiquitination of R6 acts as a signal for lysosomal degradation. In this regard, 
we treated HEK-293 cells with ammonium chloride and leupeptin, two 
compounds that impair lysosomal function. In cells expressing only R6, the 
action of the lysosomal inhibitors produced an accumulation of the steady-state 
levels of the R6 protein (Fig. 6A, lane 2; Fig. 6B), suggesting an involvement of 
the autophagic pathway in the regular degradation of R6. In cells co-expressing 
R6 and the laforin-malin complex, the treatment with the lysosomal inhibitors 
produced the accumulation of higher levels of the R6 protein (Fig. 6A, lane 5; 
Fig. 6B) in comparison to untreated cells. These data suggest that the 
downregulation of R6 protein occurs mainly through the lysosomal pathway. 
These results are in agreement with the evidence reported above that R6 was 
mono/multiubiquitinated and, when polyubiquitinated, it was by K63-linked 
ubiquitin chains (Fig. 4), which are recognized signals for autophagic 
degradation. 
 
3.5. R6, laforin and malin co-localize with endogenous glycogen synthase 
in N2a cells 
Finally, we also studied the subcellular localization of R6, laforin and malin in 
N2a cells. To this end, we transfected N2a cells with the same EYFP-R6 and 
CFP-laforin tagged plasmids used for the FRET analysis (see above; Fig. 2B). 
We also co-transfected the cells with a HA-tagged malin construct and 
performed an immunocytochemical detection using appropriated antibodies. As 
it is shown in Figure 7A, we detected R6 in structures occupying almost all the 
cytoplasm of the N2a cells, although occasionally, R6 presented a patched-
pattern as well (data not shown). In these structures, we were also able to 
detect the presence of laforin and malin, evidencing a co-localization of the 
three proteins in these subcellular localizations (Fig 7B). As R6 has glycogenic 
activity and has a carbohydrate binding module on its structure, we checked 
whether other components of the glycogenic machinery co-localized with R6. 
With this aim, we used a specific antibody in order to detect endogenous 
glycogen synthase (GS), one of the main components of the glycogenic 
machinery. We found that glycogen synthase co-localized in structures where 
R6 and laforin were also present (Fig. 7C). All these results suggest that the 
four proteins, R6, laforin, malin and GS are localized in the same structures, 
possibly sites of glycogen synthesis, revealing a common role of these proteins 
on the regulation of glycogen homeostasis in N2a cells. Binding of malin to 
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these structures does not depend on the presence of laforin, since after 
silencing laforin expression, malin still co-localized with R6 and glycogen 
synthase (Supplementary Fig. S1), probably because of its capacity to interact 
directly with components of the glycogenic machinery (glycogen synthase, 
neuronatin) [(Lohi et al. , 2005), (Sharma et al. , 2011)]. 
 
 
4. DISCUSSION 
Lafora disease (LD, OMIM 254780) is a fatal progressive myoclonus epilepsy 
characterized by epilepsy, neurodegeneration and accumulation of 
polyglucosan inclusions (Lafora bodies) in the brain and other peripheral tissues 
[(Gentry et al. , 2012), (Roma-Mateo et al. , 2012)]. Since one of the hallmarks 
of the disease is the accumulation of insoluble poorly-branched forms of 
glycogen, it has been suggested that LD is related to other diseases in which 
glycogen homeostasis is disturbed. The study of the molecular basis of LD has 
provided new concepts to understand the regulation of glycogen formation. For 
example, it has been reported that glycogen synthase, in addition to adding new 
glucose molecules to the glycogen chain, it also incorporates by error glucose 
moieties that are phosphorylated (Tagliabracci et al. , 2011). The presence of 
phosphate in the glycogen molecule impairs the formation of regular branched 
chains, resulting in a poorly-branched phosphorylated insoluble polyglucosan. 
One of the genes related to LD (EPM2A) encodes laforin, a glucan phosphatase 
involved in the dephosphorylation of glycogen. In the absence of laforin, 
glycogen remains phosphorylated leading to the formation of Lafora bodies 
(Gentry, Roma-Mateo, 2012). In addition, laforin interacts with the product of the 
second gene related to LD (EPM2B), named malin, an E3-ubiquitin ligase of the 
RING type [(Gentry et al. , 2005), (Lohi et al. , 2005)]. Laforin and malin form a 
functional complex in which laforin recruits specific substrates to be 
ubiquitinated by malin. 
 One of the first characterized substrates of the laforin-malin complex was 
R5/PTG (PPP1R3C), a glycogen targeting subunit of protein phosphatase PP1. 
Results from different groups have demonstrated that in cellular models, the 
laforin-malin complex ubiquitinates R5/PTG, decreases R5/PTG protein levels 
and downregulates its glycogenic activity [(Vilchez, Ros, 2007), (Solaz-Fuster, 
Gimeno-Alcaniz, 2008), (Worby, Gentry, 2008)]. It has also been reported that 
the laforin-malin complex also downregulates the activity of glycogen synthase 
(GS) (Vilchez, Ros, 2007), glycogen debranching enzyme (GDE/AGL) (Cheng 
et al. , 2007) and neuronatin, a small protein that stimulates glycogenesis 
(Sharma et al. , 2011). All these results point to a major role of the laforin-malin 
complex in the regulation of glycogen biosynthesis. The action of the laforin-
malin complex becomes crucial in the neurons, since in the absence of a 
functional laforin-malin complex, these cells start to accumulate poorly 
branched polyglucosans (Lafora bodies). In regular conditions, neurons do not 
accumulate glycogen since they have all the glycogenic machinery in the 
inactivated state (Vilchez, Ros, 2007). However, the expression of R5/PTG in 
these cells induces glycogen synthesis (Vilchez, Ros, 2007) and defects in the 
laforin-malin complex also induce the formation of polyglucosan bodies. The 
relationship between the laforin-malin complex and R5/PTG became evident 
when it was demonstrated that mice with deficiencies in both laforin and 
R5/PTG did not accumulate polyglucosan bodies (Turnbull et al. , 2011). 
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 In this work we have extended the analysis of the functionality of the 
laforin-malin complex on glycogen biosynthesis to an additional PP1 targeting 
subunit present in brain, namely PPP1R3D or R6. This is a glycogen binding 
protein of 33 kDa widely distributed in a variety of tissues (Armstrong, Browne, 
1997). This glycogenic subunit is particularly interesting since we have recently 
described that, in pancreatic beta cells, it participates in the regulation of the 
phosphorylation status and activity of the catalytic subunit of the AMPK 
complex, a key cellular metabolic sensor (Garcia-Haro, Garcia-Gimeno, 2010), 
and this role is not shared by other PP1 glycogenic targeting subunits such as 
R5/PTG or GL. We demonstrate in this work that R6 interacts with laforin and 
that it becomes ubiquitinated by malin. In this way, R6 follows a similar way of 
regulation as R5/PTG (see above). However, we have noticed that the 
ubiquitination of R6 targets it for autophagic degradation. The fact that the 
reduction of R6 protein levels induced by the co-expression of laforin and malin 
is prevented by the presence of lysosome inhibitors (ammonium chloride and 
leupeptine) but not by the presence of a proteasome inhibitor (lactacystin) 
supports this notion. In addition, we present evidence indicating that the laforin-
malin complex mono/multiubiquitinates R6 and additionally introduces K63-
linked polyubiquitin chains, which are determinants described as signals for 
autophagic degradation. 
 
 
5. CONCLUSIONS 
Our results indicate that the laforin-malin complex plays a crucial role in 
regulating glycogen biosynthesis in neurons. This complex downregulates the 
function of different PP1 targeting subunits [R5/PTG, R6 (this work)], ensuring 
the maintenance of glycogen synthase in its phosphorylated inactive state, 
preventing in this way glycogen biosynthesis. In the absence of a functional 
laforin-malin complex, the glycogenic activity of R5/PTG and R6 increases, 
leading to the accumulation of poorly-branched glycogen in cells that do not 
normally accumulate these deposits, what might trigger the death of the 
neurons. 
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FIGURE LEGENDS 
Figure 1: R6 interacts with laforin by yeast two-hybrid analysis. Left panel: 
yeast THY-AP4 strain was transformed with plasmids pBTM-R6 (LexA-R6) and 
pACT2 (GAD), pACT2-malin (GAD-malin) or pACT2-laforin (GAD-laforin), or 
with plasmid pGADT7-R6 (GAD-R6) and plasmids pBTM (LexA), pBTM-malin 
(LexA-malin) and pEG202-laforin (LexA-laforin). Protein interaction was 
estimated using the yeast two-hybrid system, by measuring the β-galactosidase 
activity. Values correspond to means from at least 6 different transformants (± 
SD, standard deviation). Right panel, protein expression analyzed by Western 
blotting using anti-HA antibodies (for the GAD-fusions) and anti-LexA (for the 
LexA-fusions) of three independent transformants. 
 
Figure 2: R6 interacts with laforin in mammalian N2a cells. A) Laforin co-
immunoprecipitates with R6. Protein extracts were prepared from N2a cells 
transfected with pCMV-HA-laforin and pCMV-myc-R6. One μL of anti-myc 
antibody was used to immunoprecipitate the extracts, followed by immunoblot 
analysis with anti-HA (upper panel) and anti-myc (lower panel) antibodies (IP). 
Crude extracts (CE, 20 μg) were also analyzed by immunoblotting with the 
indicated antibodies. B) FRET analysis. N2a cells transfected with CFP-laforin 
and EYFP-R6 were fixed using paraformaldehyde followed by FRET analysis 
using FRET photobleaching technique as described in Material & Methods. On 
the left, EYFP-R6 was used as a FRET acceptor (upper panels) and CFP-
laforin as FRET donor (lower panels). The area analyzed is indicated as ROI 
(region of interest). Pre: before and Post: after depleting the acceptor 
fluorescence by photobleaching. On the right, FRET efficiency values 
correspond to means from 15 to 30 different cells (bars indicate ± SD, standard 
deviation), ***p < 0.001. The same analysis was performed using EYFP as 
acceptor control. 
 
Figure 3: The laforin-malin complex is able to ubiquitinate R6. A) HEK-293 cells 
were transfected with the indicated vectors. Cells were then lysed and 
ubiquitinated proteins purified by metal-affinity chromatography. Bound material 
(Bound) as well as the clarified extract (CE, 50 μg) was analyzed by SDS-PAGE 
and immunoblotting using anti-Flag antibodies. Clarified extract was also 
analyzed using anti-HA antibodies. (+1Ub, +2Ub, indicates the position of R6 
derivatives containing one or two ubiquitin moieties). B) HEK-293 cells were 
transfected with pCMV(empty plasmid) or pCMV-myc-R5 and the indicated 
combination of plasmids. Cell extracts were analyzed as described above, but 
using anti-myc antibodies. C) HEK-293 cells transfected with pCMV-Mdm2 and 
the indicated combination of plasmids were analyzed as described in part A). 
Clarified extract was also analyzed with anti-Mdm2 antibodies. 
 
Figure 4: The laforin-malin complex promotes mono/multi- and 
polyubiquitination of R6. HEK-293 cells were transfected with the indicated 
vectors and twenty-four hours after transfection treated with 25 μM MG132 for 6 
hours. Then, ubiquitinated proteins were purified by metal-affinity 
chromatography. Clarified extracts (CE, 50 μg) and bound material (Bound) 
were analyzed by immunoblotting using anti-myc antibodies. Clarified extracts 
were also analyzed with anti-HA antibodies. 
 
15	
	
Figure 5: The laforin-malin complex modulates R6 glycogenic activity. A) R6 
glycogenic activity in N2a cells is dose-dependent. N2a cells were transfected 
using 1 μg (R6) or 1/3 μg (R6/3) of pFlag-R6 plasmid. Forty-eight hours after 
transfection, the amount of glycogen was determined as described in Material 
and Methods. On the right panel, a representative Western blot analysis (using 
anti-Flag) of protein expression in the cell extracts (20 μg) used for the glycogen 
determination is shown. The same extracts were analyzed with anti-tubulin as 
loading control. B) Effect of R6 on glycogen biosynthesis enzymes. Left panel, 
N2a cells were transfected using 1 μg of pFlag-R6 or empty plasmid. Twenty-
four hours after transfection, cell extracts (20 μg) were analyzed by western 
blotting using the corresponding antibodies: anti-glycogen synthase (notice the 
faster migrating bands corresponding to dephosphorylated forms of GS), anti-
phosphoSer641 glycogen synthase and anti-Flag antibodies. Tubulin was also 
detected and used as loading control. Right panel, a yeast two-hybrid analysis 
of R6 and glycogen phosphorylase. Yeast THY-AP4 strain was transformed 
with plasmids pEG202-Phosphorylase (LexA-Ph) and pGADT7-R6 (GAD-R6), 
or the corresponding empty plasmids. Protein interaction was estimated using 
the yeast two-hybrid system, by measuring the β-galactosidase activity. Values 
correspond to means from at least 6 different transformants (± SD, standard 
deviation). C) The laforin-malin complex downregulates R6 glycogenic activity. 
Left panel, N2a cells were transfected with pFlag (empty vector), pFlag-R6 (R6) 
or pFlag-R6 with pCMV-HA-laforin and pcDNA3-HA-malin (R6 + Laf/Mal). Forty-
eight hours after transfection, the amount of glycogen was determined as 
described in Material and Methods. Glycogen content was expressed as a 
percentage of the amount of glycogen present when pFlag-R6 was expressed. 
Bars indicate standard deviation of three independent experiments (**p < 0.01). 
Right panel, a representative Western blot analysis (using anti-Flag and anti-
HA) of protein expression in the cell extracts (20 μg) used for the glycogen 
determination is shown. The same extracts were analyzed with anti-tubulin as 
loading control. 
 
Figure 6: R6 ubiquitination acts as a signal for autophagic degradation. A) 
HEK-293 cells were transfected with the indicated vectors. Eighteen hours after 
transfection, cells were treated with ammonium chloride (20 mM)/ leupeptin 
(100 μM) or lactacystin (5 μM) for 6 hours. Then, cells were lysed and the 
extracts (20μg) were analyzed by immunoblotting using the indicated antibodies 
(anti-myc, anti-HA and anti-tubulin). B) The intensity of the bands related to the 
levels of tubulin is plotted (mean of four different experiments). Bars indicate 
standard deviation; *p < 0.05; **p < 0.01. 
 
Figure 7: Co-localization of R6, laforin, malin and glycogen synthase in N2a 
cells. A) N2a cells were transfected with pEYFP-R6 plasmid and treated with 
DAPI to stain the nucleus. The subcellular localization of EYFP-R6 was carried 
out as described in Material and Methods. The three images were subjected to 
merge analysis. B) N2a cells were co-transfected with pEYFP-R6, pCFP-laforin 
and pcDNA3-HA-malin. The subcellular localization of EYFP-R6, CFP-laforin 
and HA-malin was carried out as described in Material and Methods. Images 
were obtained by using confocal microscopy as described in Material and 
Methods and magnified x2.5 as indicated (bars indicate 20 m). The three 
images were subjected to merge analysis. C) N2a cells were transfected with 
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plasmids as indicated in B). The subcellular localization of EYFP-R6, CFP-
laforin and endogenous glycogen synthase was carried out as indicated in 
Materials and Methods (anti-glycogen synthase was used as primary antibody 
and Alexa-Flour 633 as secondary antibody). Confocal images were magnified 
as indicated (bars indicate 10 m) and subjected to merge analysis. 
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